Cancer cells use metabolic fuel to weaken T cells in the endoplasmic reticulum

New research reveals cancer cells may use metabolic fuel to alter protein behavior and weaken immune T cells, exposing new potential targets for cancer immunotherapies. Rockefeller University scientists created a comprehensive map of metabolite-protein interactions, identifying SLC33A1 as a regulator that removes oxidized glutathione from the endoplasmic reticulum. Losing it damages protein-folding enzymes and disrupts cell quality control. The team now studies pancreatic cancer, where high glutathione levels could make SLC33A1 a drug target. Experts caution the findings map unknown cellular circuitry rather than proving a new treatment.